{"id":"olopatadine-nasal-spray","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Bitter taste"},{"rate":null,"effect":"Nasal irritation"},{"rate":null,"effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL1189432","moleculeType":"Small molecule","molecularWeight":"337.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olopatadine works through dual action: it competitively antagonizes H1 histamine receptors on nasal tissues, preventing histamine-induced symptoms like itching and congestion, while also stabilizing mast cells to reduce the release of inflammatory mediators. This combination provides both immediate symptom relief and longer-term reduction in allergic inflammation.","oneSentence":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the nasal mucosa.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:08.481Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (nasal symptoms)"}]},"trialDetails":[{"nctId":"NCT06126952","phase":"PHASE2","title":"Azelastine Allergen Chamber - Onset of Action Study","status":"COMPLETED","sponsor":"MEDA Pharma GmbH & Co. KG","startDate":"2023-10-30","conditions":"Seasonal Allergic Rhinitis","enrollment":84},{"nctId":"NCT05314621","phase":"PHASE4","title":"A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Andover Research Eye Institute","startDate":"2021-12-31","conditions":"Allergic Conjunctivitis","enrollment":61},{"nctId":"NCT05129306","phase":"","title":"Impact of RYALTRIS® Nasal Spray on Patients' Reported Outcomes","status":"WITHDRAWN","sponsor":"Community and Patient Preference Research Pty Ltd","startDate":"2021-11-17","conditions":"Allergic Rhinitis","enrollment":""},{"nctId":"NCT02318303","phase":"PHASE2","title":"To Study GSP 301 in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2014-12","conditions":"Seasonal Allergic Rhinitis","enrollment":1111},{"nctId":"NCT02709538","phase":"PHASE3","title":"Long Term Safety and Efficacy of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-04","conditions":"Perennial Allergic Rhinitis","enrollment":601},{"nctId":"NCT03463031","phase":"PHASE3","title":"Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2018-03-16","conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":446},{"nctId":"NCT02631551","phase":"PHASE3","title":"Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-03","conditions":"Seasonal Allergic Rhinitis","enrollment":1180},{"nctId":"NCT03444506","phase":"PHASE2","title":"Efficacy and Safety of Fixed Dose Combination (FDC) of Olopatadine Hydrochloride and Mometasone Furoate Nasal Spray (Molo; Also Referred as GSP 301) in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Pharmaceuticals Ltd. India","startDate":"2014-01-27","conditions":"Seasonal Allergic Rhinitis","enrollment":180},{"nctId":"NCT02870205","phase":"PHASE3","title":"Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Glenmark Specialty S.A.","startDate":"2016-08","conditions":"Seasonal Allergic Rhinitis (SAR)","enrollment":1176},{"nctId":"NCT00789555","phase":"PHASE4","title":"Safety of PATANASE Nasal Spray in Patients With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-11","conditions":"Perennial Allergic Rhinitis","enrollment":1260},{"nctId":"NCT00578331","phase":"PHASE3","title":"Safety Study of Olopatadine Nasal Spray","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2006-12","conditions":"Perennial Allergic Rhinitis","enrollment":890},{"nctId":"NCT01700192","phase":"PHASE3","title":"Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2013-01","conditions":"Rhinitis, Allergic, Perennial, Rhinitis, Allergic, Nonseasonal","enrollment":1482},{"nctId":"NCT00562159","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":439},{"nctId":"NCT00550550","phase":"PHASE3","title":"Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","status":"COMPLETED","sponsor":"ALK-Abelló A/S","startDate":"2007-11","conditions":"Rhinoconjunctivitis, Rhinitis, Conjunctivitis","enrollment":345},{"nctId":"NCT01007253","phase":"PHASE4","title":"Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2009-11","conditions":"Seasonal Allergic Rhinitis","enrollment":21},{"nctId":"NCT01076439","phase":"PHASE4","title":"An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo","status":"WITHDRAWN","sponsor":"ORA, Inc.","startDate":"","conditions":"Allergic Rhinitis","enrollment":""},{"nctId":"NCT00979615","phase":"PHASE4","title":"Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-09","conditions":"Vasomotor Rhinitis","enrollment":129},{"nctId":"NCT00845195","phase":"PHASE4","title":"Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2009-03","conditions":"Seasonal Allergic Rhinitis","enrollment":150},{"nctId":"NCT00691665","phase":"PHASE4","title":"Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-05","conditions":"Seasonal Allergic Rhinitis","enrollment":130},{"nctId":"NCT00794144","phase":"PHASE2","title":"Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Allergic Rhinitis","enrollment":132},{"nctId":"NCT00578929","phase":"PHASE3","title":"Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2007-09","conditions":"Seasonal Allergic Rhinitis","enrollment":2388},{"nctId":"NCT00772304","phase":"PHASE4","title":"Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2008-10","conditions":"Allergic Rhinitis","enrollment":102},{"nctId":"NCT00655109","phase":"PHASE4","title":"A Comparison of Olopatadine and Fluticasone in Patients With Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Greiner, Jack V., OD DO PhD","startDate":"2008-02","conditions":"Conjunctivitis, Allergic","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Olopatadine Nasal Spray","genericName":"Olopatadine Nasal Spray","companyName":"ORA, Inc.","companyId":"ora-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olopatadine is a selective H1-receptor antagonist and mast cell stabilizer that blocks histamine-mediated allergic responses in the nasal mucosa. Used for Allergic rhinitis (nasal symptoms).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}